yellow fever virus


Summary: The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.

Top Publications

  1. Rice C, Lenches E, Eddy S, Shin S, Sheets R, Strauss J. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 1985;229:726-33 pubmed
    The sequence of the entire RNA genome of the type flavivirus, yellow fever virus, has been obtained...
  2. Pacca C, Severino A, Mondini A, Rahal P, D avila S, Cordeiro J, et al. RNA interference inhibits yellow fever virus replication in vitro and in vivo. Virus Genes. 2009;38:224-31 pubmed publisher
    ..The histopathologic analysis demonstrated an important protection of the central nervous system by RNAi after 10 days of viral challenge. Our data suggests that RNAi is a potential viable therapeutic weapon against yellow fever. ..
  3. Radonic A, Thulke S, Bae H, Muller M, Siegert W, Nitsche A. Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and Cytomegalovirus infections. Virol J. 2005;2:7 pubmed
    ..cell lines were infected with Cytomegalovirus, Human Herpesvirus-6, Camelpox virus, SARS coronavirus or Yellow fever virus. The expression levels of these genes and the viral replication were determined by real-time PCR...
  4. Kuno G, Chang G. Characterization of Sepik and Entebbe bat viruses closely related to yellow fever virus. Am J Trop Med Hyg. 2006;75:1165-70 pubmed
    b>Yellow fever virus has a special place in medical history as the first animal virus isolated and as the prototype virus in the genus Flavivirus, which contains many serious human pathogens...
  5. Löhr K, Knox J, Phong W, Ma N, Yin Z, Sampath A, et al. Yellow fever virus NS3 protease: peptide-inhibition studies. J Gen Virol. 2007;88:2223-7 pubmed
    A recombinant form of yellow fever virus (YFV) NS3 protease, linked via a nonapeptide to the minimal NS2B co-factor sequence (CF40-gly-NS3pro190), was expressed in Escherichia coli and shown to be catalytically active...
  6. Meier K, Gardner C, Khoretonenko M, Klimstra W, Ryman K. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009;5:e1000614 pubmed publisher
    Mosquito-borne yellow fever virus (YFV) causes highly lethal, viscerotropic disease in humans and non-human primates...
  7. van den Hurk A, McElroy K, Pyke A, McGee C, Hall Mendelin S, Day A, et al. Vector competence of Australian mosquitoes for yellow fever virus. Am J Trop Med Hyg. 2011;85:446-51 pubmed publisher
    The vector competence of Australian mosquitoes for yellow fever virus (YFV) was evaluated. Infection and transmission rates in Cairns and Townsville populations of Aedes aegypti and a Brisbane strain of Ae...
  8. Lourenco de Oliveira R, Vazeille M, de Filippis A, Failloux A. Aedes aegypti in Brazil: genetically differentiated populations with high susceptibility to dengue and yellow fever viruses. Trans R Soc Trop Med Hyg. 2004;98:43-54 pubmed
    ..samples collected in the endemic and transition areas of sylvatic yellow fever were highly susceptible to yellow fever virus. Boa Vista, a border city between Brazil and Venezuela, and Rio de Janeiro in the Southeast region are ..
  9. Buckwold V, Wei J, Wenzel Mathers M, Russell J. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob Agents Chemother. 2003;47:2293-8 pubmed
    ..combination analysis utilizing related members of the family Flaviviridae, bovine viral diarrhea virus and yellow fever virus, revealed significant direct synergistic interactions between these drugs' antiviral activities that might ..

More Information

Publications149 found, 100 shown here

  1. Co M, Kilpatrick E, Rothman A. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology. 2009;128:e718-27 pubmed publisher
    Management of yellow fever is focused on the prevention of illness by the use of the yellow fever virus (YFV) 17D vaccine...
  2. Ellis B, Sang R, Horne K, Higgs S, Wesson D. Yellow fever virus susceptibility of two mosquito vectors from Kenya, East Africa. Trans R Soc Trop Med Hyg. 2012;106:387-9 pubmed publisher
    ..Stegomyia) simpsoni s.l. mosquito species. Using first filial generation mosquitoes and a low passage yellow fever virus, this study demonstrated that although A. aegypti s.l. is a competent vector, A. simpsoni s.l...
  3. Bryant J, Vasconcelos P, Rijnbrand R, Mutebi J, Higgs S, Barrett A. Size heterogeneity in the 3' noncoding region of South American isolates of yellow fever virus. J Virol. 2005;79:3807-21 pubmed
    ..Previous studies of yellow fever virus (YFV) and dengue virus have found that modifications to the 3' NCR are sometimes associated with attenuation ..
  4. Op De Beeck A, Rouille Y, Caron M, Duvet S, Dubuisson J. The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals. J Virol. 2004;78:12591-602 pubmed
    ..In this work, we looked for potential subcellular localization signals in the yellow fever virus envelope proteins...
  5. Weidmann M, Faye O, Faye O, Kranaster R, Marx A, Nunes M, et al. Improved LNA probe-based assay for the detection of African and South American yellow fever virus strains. J Clin Virol. 2010;48:187-92 pubmed
    Real-time assays for Yellow fever virus (YFV) would help to improve acute diagnostics in outbreak investigations. To develop a real-time assay for YFV able to detect African and South American strains...
  6. Onyango C, Ofula V, Sang R, Konongoi S, Sow A, De Cock K, et al. Yellow fever outbreak, Imatong, southern Sudan. Emerg Infect Dis. 2004;10:1063-8 pubmed reverse transcription-polymerase chain reaction with both the genus Flavivirus-reactive primers and yellow fever virus-specific primers...
  7. Querec T, Akondy R, Lee E, Cao W, Nakaya H, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10:116-125 pubmed publisher
    ..A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy. ..
  8. Chambers T, Nickells M. Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. J Virol. 2001;75:10912-22 pubmed
    A neuroadapted strain of yellow fever virus (YFV) 17D derived from a multiply mouse brain-passaged virus (Porterfield YF17D) was additionally passaged in SCID and normal mice...
  9. Droll D, Krishna Murthy H, Chambers T. Yellow fever virus NS2B-NS3 protease: charged-to-alanine mutagenesis and deletion analysis define regions important for protease complex formation and function. Virology. 2000;275:335-47 pubmed publisher
    Charged-to-alanine substitutions and deletions within the yellow fever virus NS2B-NS3(181) protease were analyzed for effects on protease function...
  10. Julander J, Shafer K, Smee D, Morrey J, Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009;53:202-9 pubmed publisher
    Treatment with the nucleoside analog T-1106 was previously shown to be effective in a hamster model of yellow fever virus (YFV) disease, even though it had only slight activity in cell culture...
  11. Queiroz S, Silva A, Santos J, Marques E, Bertani G, Gil L. Construction of yellow fever virus subgenomic replicons by yeast-based homologous recombination cloning technique. An Acad Bras Cienc. 2013;85:159-68 pubmed
    ..In this study we described the construction of subgenomic replicons of yellow fever virus by yeast-based homologous recombination technique...
  12. Ono L, Wollinger W, Rocco I, Coimbra T, Gorin P, Sierakowski M. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res. 2003;60:201-8 pubmed
    ..Their activities against yellow fever virus (YFV; BeH111 strain) and dengue 1 virus (DEN-1; Hawaii strain) were evaluated...
  13. Vasconcelos P, Bryant J, da Rosa T, Tesh R, Rodrigues S, Barrett A. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis. 2004;10:1578-84 pubmed
    An analysis of 79 yellow fever virus (YFV) isolates collected from 1935 to 2001 in Brazil showed a single genotype (South America I) circulating in the country, with the exception of a single strain from Rondonia, which represented South ..
  14. Jones C, Patkar C, Kuhn R. Construction and applications of yellow fever virus replicons. Virology. 2005;331:247-59 pubmed
    Subgenomic replicons of yellow fever virus (YFV) were constructed to allow expression of heterologous reporter genes in a replication-dependent manner...
  15. Quaresma J, Barros V, Pagliari C, Fernandes E, Andrade H, Vasconcelos P, et al. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans R Soc Trop Med Hyg. 2007;101:161-8 pubmed
  16. Meneses R, Ocazionez R, Martínez J, Stashenko E. Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro. Ann Clin Microbiol Antimicrob. 2009;8:8 pubmed publisher
    ..effect of essential oils of Lippia alba, Lippia origanoides, Oreganum vulgare and Artemisia vulgaris on yellow fever virus (YFV) replication was investigated...
  17. Nunes M, Palacios G, Nunes K, Casseb S, Martins L, Quaresma J, et al. Evaluation of two molecular methods for the detection of Yellow fever virus genome. J Virol Methods. 2011;174:29-34 pubmed publisher
    b>Yellow fever virus (YFV), a member of the family Flaviviridae, genus Flavivirus is endemic to tropical areas of Africa and South America and is among the arboviruses that pose a threat to public health...
  18. Carrington C, Auguste A. Evolutionary and ecological factors underlying the tempo and distribution of yellow fever virus activity. Infect Genet Evol. 2013;13:198-210 pubmed publisher
    b>Yellow fever virus (YFV) is historically one of the most important viruses to affect human populations...
  19. Vicens R, Robert V, Pignon D, Zeller H, Ghipponi P, Digoutte J. [Yellow fever epidemic in the extreme North of Cameroon in 1990: first yellow fever virus isolation in Cameroon]. Bull World Health Organ. 1993;71:173-6 pubmed
    ..Investigations began at the start of the dry season and a strain of yellow fever virus was isolated for the first time in Cameroon...
  20. Drosten C, Göttig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-30 pubmed
    ..Crimean-Congo hemorrhagic fever virus (CCHFV), Rift Valley fever virus (RVFV), dengue virus (DENV), and yellow fever virus (YFV)...
  21. Carpp L, Galler R, Bonaldo M. Interaction between the yellow fever virus nonstructural protein NS3 and the host protein Alix contributes to the release of infectious particles. Microbes Infect. 2011;13:85-95 pubmed publisher
    ..Furthermore, we show that NS3 supplied in trans rescues this effect. We propose that the interaction between NS3 and Alix contributes to YFV release. ..
  22. Vasconcelos P, Rosa A, Rodrigues S, Rosa E, Monteiro H, Cruz A, et al. Yellow fever in Pará State, Amazon region of Brazil, 1998-1999: entomologic and epidemiologic findings. Emerg Infect Dis. 2001;7:565-9 pubmed
    ..We hypothesize that YF virus remains in an area after an outbreak by vertical transmission among Haemagogus mosquitoes. ..
  23. Mondet B, Vasconcelos P, Travassos da Rosa A, Travassos da Rosa E, Rodrigues S, Travassos Rosa J, et al. Isolation of yellow fever virus from nulliparous Haemagogus (Haemagogus) janthinomys in eastern Amazonia. Vector Borne Zoonotic Dis. 2002;2:47-50 pubmed
    ..8% for parous and 2.9% for nulliparous females. These results lead to the conclusion that vertical transmission, one of the key elements in the epidemiology of YF, occurs in South America as it does in Africa. ..
  24. Pulendran B, Miller J, Querec T, Akondy R, Moseley N, Laur O, et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198:500-7 pubmed publisher
    ..In this patient, viscerotropic disease was not due to the impaired magnitude of adaptive immunity but instead to anomalies in the innate immune system and a possible disruption of the CCR5-RANTES axis. ..
  25. Kaptein S, De Burghgraeve T, Froeyen M, Pastorino B, Alen M, Mondotte J, et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother. 2010;54:5269-80 pubmed publisher
    ..SA-17 also inhibits yellow fever virus 17D (YFV-17D) replication (EC(50) = 3.1 ± 1.0 ?g/ml [4.8 ± 1...
  26. Vazquez S, Valdés O, Pupo M, Delgado I, Alvarez M, Pelegrino J, et al. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods. 2003;110:179-84 pubmed
    ..methods for the detection of antibodies against dengue virus were modified to detect antibodies against yellow fever virus. Tests were carried out in 21 persons vaccinated with 17D and compared with the Plaque reduction ..
  27. Bonaldo M, Garratt R, Caufour P, Freire M, Rodrigues M, Nussenzweig R, et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol. 2002;315:873-85 pubmed
    ..The large deletion of six residues from the fg loop of the E protein from yellow fever virus, compared to tick-born encephalitis virus, leaves space at the dimer interface for a large insertion without ..
  28. Roukens A, Visser L. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. 2008;8:1787-95 pubmed
    ..For this population and for travellers to endemic areas, vaccination is the only effective protective measure against the disease and the spread of the virus...
  29. Ergunay K, Saygan M, Aydogan S, Litzba N, Niedrig M, Pinar A, et al. [Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey]. Mikrobiyol Bul. 2010;44:415-24 pubmed
    Dengue virus (DENV) and yellow fever virus (YFV) are two of the globally prevalent vector-borne flaviviruses...
  30. Beaty B, Tesh R, Aitken T. Transovarial transmission of yellow fever virus in Stegomyia mosquitoes. Am J Trop Med Hyg. 1980;29:125-32 pubmed
    Transovarial transmission of two strains of yellow fever virus was demonstrated in three colonized geographical strains of Aedes aegypti following infection by intrathoracic inoculation...
  31. Vasconcelos P, Luna E, Galler R, Silva L, Coimbra T, Barros V, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91-7 pubmed
    ..She then developed icterus, renal failure, and haemorrhagic diathesis, and died after 6 days of illness. Yellow fever virus was recovered in suckling mice and C6/36 cells from blood in both cases, as well as from fragments of liver, ..
  32. Souza M, Freire M, Schulze E, Gaspar L, Castilho L. Production of yellow fever virus in microcarrier-based Vero cell cultures. Vaccine. 2009;27:6420-3 pubmed publisher
    In this work, the propagation of the 17DD yellow fever virus in Vero cells grown on Cytodex-1 microcarriers was evaluated...
  33. Jentes E, Poumerol G, Gershman M, Hill D, Lemarchand J, Lewis R, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622-32 pubmed publisher
    ..vaccine have drawn attention to the need to revisit criteria for the designation of areas with risk for yellow fever virus activity, and to revise the vaccine recommendations for international travel...
  34. Domingo C, Patel P, Yillah J, Weidmann M, Mendez J, Nakouné E, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-60 pubmed publisher
    ..We demonstrate reliable detection by both assays of different strains of yellow fever virus with improved sensitivity and specificity...
  35. Kwallah A, Inoue S, Muigai A, Kubo T, Sang R, Morita K, et al. A real-time reverse transcription loop-mediated isothermal amplification assay for the rapid detection of yellow fever virus. J Virol Methods. 2013;193:23-7 pubmed publisher
    ..Detection of yellow fever virus (YFV) in Africa remains a challenge due to a lack of highly specific tests...
  36. Molenkamp R, Kooi E, Lucassen M, Greve S, Thijssen J, Spaan W, et al. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J Virol. 2003;77:1644-8 pubmed
    Chimeric yellow fever virus (YF) RNAs were constructed in which the YF structural genes were replaced by the hepatitis C virus (HCV) structural genes or fusions between the YF and HCV structural genes...
  37. Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol. 2008;82:6024-33 pubmed publisher
    The yellow fever virus (YFV) 17D strain is one of the most effective live vaccines for human use, but the in vivo mechanisms for virulence attenuation of the vaccine and the corresponding molecular determinants remain elusive...
  38. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009;9:741-7 pubmed publisher
    ..Here I review how these developments are yielding insights into the mechanism of action of the yellow fever vaccine, one of the most successful vaccines ever developed, and the broader implications for vaccinology. ..
  39. Wamala J, Malimbo M, Okot C, Atai Omoruto A, Tenywa E, Miller J, et al. Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010-January 2011. Int J Infect Dis. 2012;16:e536-42 pubmed publisher
    ..The wide geographical case dispersion as well as the male and older age preponderance suggests transmission during the outbreak was largely sylvatic and related to occupational activities around forests. ..
  40. Monath T, Liu J, Kanesa Thasan N, Myers G, Nichols R, Deary A, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006;103:6694-9 pubmed
    ..ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease. ..
  41. Corver J, Lenches E, Smith K, Robison R, Sando T, Strauss E, et al. Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization. J Virol. 2003;77:2265-70 pubmed
    We present fine mapping of a cis-acting nucleotide sequence found in the 5' region of yellow fever virus genomic RNA that is required for RNA replication...
  42. McElroy K, Tsetsarkin K, Vanlandingham D, Higgs S. Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. J Gen Virol. 2006;87:2993-3001 pubmed
    ..b>Yellow fever virus (YFV) is an important arbovirus and the prototype member of the family Flaviviridae...
  43. Julander J, Furuta Y, Shafer K, Sidwell R. Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrob Agents Chemother. 2007;51:1962-6 pubmed
    b>Yellow fever virus (YFV) causes 30,000 deaths worldwide, despite the availability of a vaccine...
  44. Mantel N, Aguirre M, Gulia S, Girerd Chambaz Y, Colombani S, Moste C, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods. 2008;151:40-6 pubmed publisher
    ..Reproducibility of RNA extraction was ensured by automation of the process (yield>or=50%), and infectious virus was isolated in >or=80% of PCR-positive sera from immune monkeys. ..
  45. Bryant J, Barrett A. Comparative phylogenies of yellow fever isolates from Peru and Brazil. FEMS Immunol Med Microbiol. 2003;39:103-18 pubmed
    We recently reported phylogenetic evidence to support the presence of enzootic transmission foci of yellow fever virus (YFV) in Peru [Bryant et al., Emerg. Infect. Dis. (2003)]...
  46. Struchiner C, Luz P, Dourado I, Sato H, Aguiar S, Ribeiro J, et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect. 2004;132:939-46 pubmed
    ..Although vaccination of YF endemic regions is necessary to maintain low disease prevalence, preventive administration of YF vaccine to the entire population should be cautiously analysed. ..
  47. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, et al. Structure and function of flavivirus NS5 methyltransferase. J Virol. 2007;81:3891-903 pubmed
    ..The results demonstrate that the N-7 methylation activity is essential for the WNV life cycle and, thus, methyltransferase represents a novel target for flavivirus therapy. ..
  48. Nogueira R, Nogueira A, Pereira M, Rodrigues M, Galler R, Bonaldo M. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome. Virol J. 2011;8:127 pubmed publisher
    ..It is likely that additional antigens and recombinant virus formulations will be necessary to generate a protective response. ..
  49. Daffis S, Kontermann R, Korimbocus J, Zeller H, Klenk H, Ter Meulen J. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology. 2005;337:262-72 pubmed
    ..Mutations in this major neutralizing epitope of YFV thus do not seem to carry the risk of immune escape in persons immunized with the YFV-17D vaccine. ..
  50. Quaresma J, Barros V, Pagliari C, Fernandes E, Guedes F, Takakura C, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology. 2006;345:22-30 pubmed
    ..Our finding supports the key effect of the yellow fever virus in hepatocyte injury, resulting in prevalence of apoptosis over necrosis, aside from a TGF-beta action ..
  51. Barrett A, Teuwen D. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol. 2009;21:308-13 pubmed publisher
    ..At present, the mechanism(s) of SAEs is(are) poorly understood but our advances in understanding the immune response induced by the vaccine have promise to help elucidate the mechanism of SAEs...
  52. Auguste A, Lemey P, Pybus O, Suchard M, Salas R, Adesiyun A, et al. Yellow fever virus maintenance in Trinidad and its dispersal throughout the Americas. J Virol. 2010;84:9967-77 pubmed publisher
    Trinidad, like many other American regions, experiences repeated epizootics of yellow fever virus (YFV)...
  53. Quaresma J, Barros V, Fernandes E, Pagliari C, Takakura C, da Costa Vasconcelos P, et al. Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop. 2005;94:116-27 pubmed
    ..It is recommended that therapeutic regimens for serious cases should include measures to protect against apoptosis. ..
  54. Santos A, Bertho A, Dias D, Santos J, Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz. 2005;100:331-7 pubmed
    ..Our data provide a basis for further studies on immunological behavior of the YF 17DD vaccine. ..
  55. Palmer D, Fernandez S, Bisbing J, Peachman K, Rao M, Barvir D, et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol. 2007;88:148-56 pubmed
    The yellow fever virus attenuated 17D vaccine strain is a safe and effective vaccine and a valuable model system for evaluating immune responses against attenuated viral variants...
  56. Galler R, Post P, Santos C, Ferreira I. Genetic variability among yellow fever virus 17D substrains. Vaccine. 1998;16:1024-8 pubmed
    ..Since the exact passage histories of these viruses is known it was possible to calculate, for each strain, the number of accumulated changes per passage. Based on these data the 17DD strain was the most genetically stable virus. ..
  57. Gubler D. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?. Comp Immunol Microbiol Infect Dis. 2004;27:319-30 pubmed
    ..In the last 25 years of the 20th century, however, there was a resurgence of yellow fever in Africa, and of dengue worldwide. The factors responsible for this resurgence are discussed, as are current options for prevention and control. ..
  58. Pugachev K, Guirakhoo F, Mitchell F, Ocran S, Parsons M, Johnson B, et al. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004;71:639-45 pubmed
    ..These chimeras have the potential for use as diagnostic reagents and vaccines against SLE and WN. ..
  59. Wu J, Bera A, Kuhn R, Smith J. Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J Virol. 2005;79:10268-77 pubmed
    b>Yellow fever virus (YFV), a member of the Flavivirus genus, has a plus-sense RNA genome encoding a single polyprotein. Viral protein NS3 includes a protease and a helicase that are essential to virus replication and to RNA capping. The 1...
  60. Bonaldo M, Garratt R, Freire M, Galler R. Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein. Cell Biochem Biophys. 2006;44:313-24 pubmed
  61. Julander J, Ennis J, Turner J, Morrey J. Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother. 2011;55:2067-73 pubmed publisher
    ..dose prior to virus infection, which resulted in a dose-responsive, protective effect in a hamster model of yellow fever virus (YFV) disease...
  62. Warrener P, Tamura J, Collett M. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol. 1993;67:989-96 pubmed
    The nonstructural protein NS3 of the prototypic flavivirus, yellow fever virus, was investigated for possession of an NTPase activity...
  63. Monath T. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20 pubmed
    ..New applications of yellow fever 17D virus as a vector for foreign genes hold considerable promise as a means of developing new vaccines against other viruses, and possibly against cancers. ..
  64. Patkar C, Jones C, Chang Y, Warrier R, Kuhn R. Functional requirements of the yellow fever virus capsid protein. J Virol. 2007;81:6471-81 pubmed publisher
    ..By use of a trans-packaging system that involved packaging a yellow fever virus (YFV) replicon into pseudo-infectious particles by supplying the YFV structural proteins using a Sindbis ..
  65. Pugachev K, Guirakhoo F, Ocran S, Mitchell F, Parsons M, Penal C, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78:1032-8 pubmed
    Three consecutive plaque purifications of four chimeric yellow fever virus-dengue virus (ChimeriVax-DEN) vaccine candidates against dengue virus types 1 to 4 were performed...
  66. Liniger M, Zuniga A, Naim H. Use of viral vectors for the development of vaccines. Expert Rev Vaccines. 2007;6:255-66 pubmed
    ..Most notably, novel vaccines based on live, recombinant vectors may combine the induction of broad, strong and persistent immune responses with acceptable safety profiles. ..
  67. Querec T, Pulendran B. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D. Adv Exp Med Biol. 2007;590:43-53 pubmed
  68. Mason R, Tauraso N, Spertzel R, Ginn R. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25:539-44 pubmed
    ..After challenge with Asibi strain YF virus, antibody titers of all three tests increaed equally. In rhesus monkeys PN antibody titers were well correlated with YF immunity, whereas HI and CF antibody titers were not. ..
  69. Germi R, Crance J, Garin D, Guimet J, Lortat Jacob H, Ruigrok R, et al. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology. 2002;292:162-8 pubmed publisher
    Dengue virus type 2 and Yellow fever virus are arthropod-borne flaviviruses causing hemorrhagic fever in humans. Identification of virus receptors is important in understanding flavivirus pathogenesis...
  70. Chambers T, Nestorowicz A, Mason P, Rice C. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73:3095-101 pubmed
  71. Arroyo J, Guirakhoo F, Fenner S, Zhang Z, Monath T, Chambers T. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75:934-42 pubmed
    A yellow fever virus (YFV)/Japanese encephalitis virus (JEV) chimera in which the structural proteins prM and E of YFV 17D are replaced with those of the JEV SA14-14-2 vaccine strain is under evaluation as a candidate vaccine against ..
  72. Belmusto Worn V, Sanchez J, McCarthy K, Nichols R, Bautista C, Magill A, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005;72:189-97 pubmed
    ..There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated. ..
  73. Barnett E. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-6 pubmed
    ..Describing host factors that would increase risk of these events and identifying potential treatment modalities for yellow fever and yellow fever vaccine-associated adverse events are subjects of intense investigation. ..
  74. Bronzoni R, Madrid M, Duarte D, Pellegrini V, Pacca C, Carmo A, et al. The small nuclear ribonucleoprotein U1A interacts with NS5 from yellow fever virus. Arch Virol. 2011;156:931-8 pubmed publisher
    ..This study shows for the first time that the yellow fever virus (YFV) NS5 protein is able to interact with U1A, a protein involved in splicing and polyadenylation...
  75. Trindade G, Santana M, Santos J, Galler R, Bonaldo M. Retention of a recombinant GFP protein expressed by the yellow fever 17D virus in the E/NS1 intergenic region in the endoplasmic reticulum. Mem Inst Oswaldo Cruz. 2012;107:262-72 pubmed
    ..Further studies should be undertaken to elucidate the causes of the ER retention of recombinant proteins expressed at the intergenic E/NS1 region of the YF 17D virus polyprotein...
  76. Monath T, Barrett A. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-95 pubmed
  77. Bae H, Drosten C, Emmerich P, Colebunders R, Hantson P, Pest S, et al. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol. 2005;33:274-80 pubmed
    ..Two YF cases were imported to Europe in the last 4 years. We characterized two yellow fever virus (YFV) isolates from severely infected patients coming back from Africa, Ivory Coast and The Gambia, by ..
  78. Dayan G, Bevilacqua J, Coleman D, Buldo A, Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ? 50 years of age. Vaccine. 2012;30:6656-64 pubmed publisher
    ..The ChimeriVax-WN02 vaccine was highly immunogenic and well tolerated among subjects ? 50 years old at all dose levels. ..
  79. Op De Beeck A, Molenkamp R, Caron M, Ben Younes A, Bredenbeek P, Dubuisson J. Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. J Virol. 2003;77:813-20 pubmed
    ..investigated the role of the transmembrane domains of prM and E in the envelope formation of the flavivirus yellow fever virus (YFV)...
  80. McElroy K, Tsetsarkin K, Vanlandingham D, Higgs S. Characterization of an infectious clone of the wild-type yellow fever virus Asibi strain that is able to infect and disseminate in mosquitoes. J Gen Virol. 2005;86:1747-51 pubmed
    ..This study describes the development of an infectious clone of the prototype yellow fever virus Asibi strain (YFV-As) with the purpose of identifying sequences or domains that influence infection dynamics ..
  81. McElroy K, Tsetsarkin K, Vanlandingham D, Higgs S. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3'non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J Trop Med Hyg. 2006;75:1158-64 pubmed
    ..Substitution of the 17D NS2A or NS4B into Asibi significantly attenuated YFV dissemination, demonstrating that this is a multigenic property. There was no difference in dissemination after substitution of the 17D 3'NCR. ..
  82. Bryant J, Holmes E, Barrett A. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007;3:e75 pubmed
    b>Yellow fever virus (YFV) remains the cause of severe morbidity and mortality in South America and Africa...
  83. Scherer C, Magness C, Steiger K, Poitinger N, Caputo C, Miner D, et al. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine. 2007;25:6458-73 pubmed
    ..Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents. ..
  84. Volk D, May F, Gandham S, Anderson A, von Lindern J, Beasley D, et al. Structure of yellow fever virus envelope protein domain III. Virology. 2009;394:12-8 pubmed publisher
    The structure of recombinant domain III of the envelope protein (rED3) of yellow fever virus (YFV), containing the major neutralization site, was determined using NMR spectroscopy...
  85. Gardner C, Ryman K. Yellow fever: a reemerging threat. Clin Lab Med. 2010;30:237-60 pubmed publisher
    ..b>Yellow fever virus (YFV) can cause devastating epidemics of potentially fatal, hemorrhagic disease...
  86. Stock N, Boschetti N, Herzog C, Appelhans M, Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine. 2012;30:989-94 pubmed publisher
    ..Using all other publically available 17D full genome sequences we compared the sequence variance of all vaccine strains and oppose a phylogenetic tree based on full genome sequences to the historical genealogy. ..
  87. Blom K, Braun M, Ivarsson M, Gonzalez V, Falconer K, Moll M, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol. 2013;190:2150-8 pubmed publisher
    The live attenuated yellow fever virus (YFV) 17D vaccine provides a good model to study immune responses to an acute viral infection in humans...
  88. Xiao S, Zhang H, Guzman H, Tesh R. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis. 2001;183:1437-44 pubmed
    ..The histopathologic changes were more severe in younger (subadult) animals. The YF-hamster model appears to be an accurate and inexpensive experimental system for studying the pathophysiology and treatment of YF. ..
  89. Co M, Terajima M, Cruz J, Ennis F, Rothman A. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 2002;293:151-63 pubmed
    b>Yellow fever virus (YFV) is a re-emerging problem despite the existence of an effective live-attenuated vaccine...
  90. McArthur M, Suderman M, Mutebi J, Xiao S, Barrett A. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol. 2003;77:1462-8 pubmed
    ..The majority of these substitutions (five of seven) fall within the envelope (E) protein at positions Q27H, D28G, D155A, K323R, and K331R. These results support an important role for the E protein in determining YF virus viscerotropism. ..
  91. Charlier N, Molenkamp R, Leyssen P, Paeshuyse J, Drosten C, Panning M, et al. Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice. J Virol. 2004;78:7418-26 pubmed
    ..flavivirus infectious cDNA was constructed by exchanging the premembrane (prM) and envelope (E) genes of the yellow fever virus vaccine strain 17D (YF17D) with the corresponding genes of Modoc virus (MOD)...
  92. Silva P, Molenkamp R, Dalebout T, Charlier N, Neyts J, Spaan W, et al. Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication. J Gen Virol. 2007;88:1738-47 pubmed
    ..In this study, the sequence requirements of the PN motif for yellow fever virus 17D (YFV) replication were determined...